Abstract: Robust optimal control of pharmacokinetic / pharmacodynamic (PK/PD) models allows for optimal drug dosage design under model uncertainties. Typical PK/PD models are highly uncertain and therefore a robust design of the drug dosage is necessary to guarantee that important health-related constraints are satisfied for all the possible values of the uncertainty. This paper shows that the responses of a simple class of PK/PD models are monotonous in the parameters and in the input. This greatly simplifies the design of a scenario-based nonlinear model predictive controller as just two scenarios are necessary to fully bound the system responses. This is illustrated with the drug dosage design for a model of erythropoietin injection, in which we also show the potential benefit of having intermediate measurements during the application of the therapy.
INTRODUCTION
Control of drug dosage is challenging as the dosage should be sufficiently high to achieve the therapeutic targets even under uncertainties and disturbances and at the same time be as low as possible to minimise side effects and reduce cost. In many cases, the way drugs act is complicated, in particular if they need to be transported to and accumulate in particular parts of the body, or if one is interested in obtaining a detailed knowledge of all the changes a certain drug causes on the regulation of transcription, translation etc., as e.g. psychotropic drugs influencing the rate of transcription in the brain [Korostynski et al., 2013] .
In this paper, we focus on regulating serum levels of hormones. This simplifies the problem as drugs can be directly injected into the blood and measurements of serum hormone concentration can be linked to desired target levels. Drug dosage is a key issue in hormone therapy as the dose positively correlates with cost and also lower dose usually yields a reduction of side effects. Optimal dosage is a difficult task and model-based optimal control seems a promising approach.
Hormones
Hormones are proteins produced by specialised cells and play an important role in the human body's inter-cellular signalling. For example, insulin is produced by beta cells in the pancreas [Leibiger et al., 2008] and stimulates in muscle and fat tissues the uptake of glucose for lipid synthesis and inhibits lipolysis [P. Sonksen and J. Sonksen, 2000] .
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Diabetes mellitus is probably the best known insulin related disease where the level of insulin is too low to lower the blood glucose level to normal conditions. This can lead to a variety of complications if this high sugar level holds for a too long period of time. Less known is hyperinsulinaemia, in which the level of insulin is too high, resulting in hypoglycemia (low blood glucose levels) that can result in loss of consciousness or even death.
Hormone therapy
There are many different approaches to treat diseases linked to hormonal deficiencies. Two are described next. First, extra hormones can be added to the body, for example by bolus injection as is typically performed by diabetic patients. This strategy increases the level of hormone. Second, an antibody can be injected, thus lowering the level of free hormones. This is for example the case for treating immune diseases linked to too high levels of cytokines [Gee et al., 2003] . Cytokines are proteins that are functionally similar to hormones, though produced less locally.
Erythropoietin therapy as motivating example
Erythropoietin (EPO) is a hormone controlling erythropoiesis, i.e. the differentiation of cells to erythrocytes (red blood cells), it is mostly produced by interstitial fibroblasts in the kidney and to a lower extent by perisinusoidal cells in the liver [Sytkowski, 2006] . EPO is best known as performance enhancing drug in endurance sports like cycling and long-distance running [Jelkmann, 2000] , where it is used to increase the haematocrit, the relative amount of red blood cells, and therefore the oxygen carrying capacity [Larsen et al., 2014] . However, direct or indirect EPO administration also serves therapeutic means [Jelkmann, 2000] . In particular, deficiency of erythrocytes (anaemia) can be due to too low levels of EPO, and thus be treated by administration of erythropoiesis-stimulating agents (ESAs), erythrocyte transfusions or administration of recombinant human erythropoietin [Schirm et al., 2013; Spivak et al., 2009] . For ESAs, the optimal dosage is as low as possible to reduce the risk of side effects, in particular cardiovascular events such as strokes, and no generally applicable optimal dosage is known yet [FDA, 2011] . The same can also be expected for direct administration of EPO. However, it should be noted that generally valid values for target and constraints are not realistic as there is a large variability even among healthy subjects, see e.g. the EPO serum concentration ranges of 3.30 mU/mL to 23.40 mU/mL [Owen and Roberts, 2011] or 5 mU/mL to 36 mU/mL [Laposata, 2010] .
Beside stimulating the production of red blood cells, erythropoietin has a number of other effects, e.g. on bone formation [McGee et al., 2012] . As the erythropoietic action occurs at lower dose than the other effects [Rölfing et al., 2014] , an erythropoietic EPO therapy should aim at keeping a dosage as low as possible, though sufficiently high to have a therapeutic effect on the red blood cell formation.
Pharmacodynamic/pharmacokinetic models (PK/PD)
Pharmacodynamic models (PD) describe the interactions of drugs and their receptors or ligands. Pharmacokinetic models (PK) describe the temporal dynamics of drug uptake and elimination. Typically, PK/PD models are studied with nominal parameter values or with parameters that follow certain distributions, e.g. are log-normally distributed [Germani et al., 2013] . This then requires in most cases Monte-Carlo simulation studies as shown in [Lunn et al., 2009] . Such an approach is computationally intensive and at the same time does not offer much insight into the rôle of the individual parameter's influence.
PK/PD models can serve for calculating optimal strategies [Fetterly et al., 2013] . A variety of control strategies has been applied to PK/PD models, for example MPC as in [Chen et al., 2012] . Parameter uncertainty was e.g. dealt with by online parameter estimation [Garcia-Gabin and Jacobsen, 2013] , or using controllers not depending on specific parameter values as in [Bullinger et al., 2000] .
Model Predictive Control under uncertainty
Due to the unavoidable uncertainty which is present in pharmacodynamic and pharmacokinetic models, the solutions from model-based methods can lead to unpredicted or even dangerous situations. It is therefore very important to consider uncertainty explicitly using robust methods. We focus here on the multi-stage nonlinear model predictive control approach presented in [Lucia et al., 2013] that considers a scenario tree of predictions for different possible values of the uncertainty, leading to satisfaction of the constraints for all possible cases of the uncertainty. We use the monotonicity properties of the model to design a simple set of scenarios that achieves a robust control strategy.
Novelty and structure of the paper
The here proposed approach uncovers the monotonicity of a class of PK/PD models and utilises this to efficiently calculate the propagation of set-bounded parametric errors. This allows for the simple design of robust optimal control strategies, which are exemplarily applied to a model of erythropoietin therapy.
After the introduction in Section 1, Section 2 presents the pharmacodynamic model and its monotonicity properties. Section 3 does the same for the pharmacokinetic model. The optimal control strategy is presented in Section 4, where it is also applied to a PK/PD model of EPO delivery. Finally, Section 5 summarises and concludes the paper.
PHARMACODYNAMIC MODEL AND MODEL ANALYSIS
Pharmacodynamics describe the interactions between drugs and their ligands. In this paper, a ligand L interacts with a drug D, forming a complex C. This is modelled as
where the flows follow the law of mass action. Thus, the association flow, v a , and dissociation flow
The following assumptions are standard for PK/PD and biochemical models. Assumption 1. In the model (1)- (2), the kinetic rate constants k a and k d in (2) are strictly positive and the concentrations L, D and C are non-negative.
The pharmacodynamic system (1) is in equilibrium
Typically, the following quantities are measured in medical applications:
Due to the positivity assumption on the kinetic rate constants, Assumption 1, the dissociation constant is positive, too. The total amount of ligand and drug are non-negative. However, the case of one or both of them being zero is trivial and thus not interesting. Therefore, we also restrict these to being strictly positive.
Monotonicity analysis of the pharmacodynamic model
At equilibrium, the following holds:
This quadratic equation has two solutions, namely
2 where, to shorten the notation, we defined
The state L is either a concentration or an amount. In both cases it is non-negative. The only non-negative solution of (3) is 
As the second derivative is positive for all L tot , dL dLtot is monotonous. From this and dL
Then, we analyse monotonicity with respect to
As the second derivative is non-negative for all D tot , L tot and K D , dL dDtot is monotonous. From this and
follows that L is monotonically increasing in D tot as the derivative w.r.t. D tot is smaller than zero for any positive
parameter.
Finally, we study the influence of
As the first derivative is positive and the second negative
Then the steady state value of the free ligand L is bounded and lies in the set
The proof of this proposition is straightforward and is omitted here for brevity.
PD model of Erythropoietin
The pharmacodynamic model of erythropoietin serves as illustration for the monotonicity analysis discussed above. For this study, the PD model of [Krzyzanski and Wyska, 2008; Schirm et al., 2013] had been simplified to fit into the framework of Model (1). In the original model, the three degradation rates are not identical, thus the original model does not have conserved moieties. while for a large quantity of drug the ligand is almost only present in the drug-bound form.
The above discussed case assumes perfect knowledge of the parameters' values. Realistically, all parameters are subjected to relatively large errors, inherent to experimental limitations and model simplifications. Figure 2 shows the uncertainty band for the free ligand under up to ±20 % additive error on L tot . The effect of simultaneous uncertainty of L tot , D tot and K D on the relative amount of free ligand is shown in Figure 3 as a function of the nominal L tot and D tot . The hereby used uncertainty range is specified in Table 1 on the following page. 
PHARMACOKINETIC MODEL AND MODEL ANALYSIS
This paper assumes that a single compartment is sufficient to describe the pharmacokinetic side. Furthermore, the total amount of ligand L tot is a conserved moiety while the drug in both free and ligand-bound form is subject to a linear decay with kinetic constant k deg . As the pharmacodynamic model operates on a much faster time scale, reaction (1) is in quasi-steady-state. Nevertheless, a straight-forward calculation shows that the total amount of the drug, D tot , is subjected to a linear decay with non-
There are commonly two ways of administering a drug: a continuous inflow and bolus injection. In this paper, we assume that the drug is added as bolus injections at regularly spaced time instances {t i , i = 1, 2, . . .}. This can be simulated by updating the initial condition at these time instances:
where t − i is the time just before and t + i the time immediately after the injection.
In the time interval t ∈ [t
], the solution of the differential equation (6) is given by
The derivative of D tot (t) with respect to the degradation rate k deg is then
]. As both k deg and D tot (t) are nonnegative, this derivative is non-positive. Therefore, for a fixed time t, D tot (t) is monotonously decreasing with increasing k deg . 
PK model of Erythropoietin
The PK models of Krzyzanski and Wyska, [ibid.] and Schirm et al., [2013] were adjusted to the simplified PD model presented in Section 2.2 by taking the same degradation constant k deg for both D and C, and thus also for D tot , and by assuming that L tot is constant.
ROBUST OPTIMAL CONTROL OF THE ERYTHROPOIETIN PK/PD MODEL
In this section we aim at finding a sequence of optimal drug injections such that the concentration of the unbound form of the drug's ligand stays below a given threshold. This is chosen here as 0.10 nM = 100 pM.
As discussed in Section 1.2, the EPO dosage should be kept sufficiently low to reduce side effects. Due to the monotonicity and to the drug being degraded over time, the maximal value of free ligand is attained just before a drug injection, see Figure 4 . This controller, denoted ROC, uses a large initial dose and subsequently a slightly lower one that just compensates the drug degradation. This controller is a feed-forward, i.e. open-loop controller and does not require any measurement. A key advantage of the monotonicity of the model is that the reachable set of the free ligand L (all the possible values of L for the given uncertainty bounds) can be obtained in a simple manner from two scenarios. These two scenarios, which are used to obtain the robust optimal control solution can be also seen in Figure 4 , middle row.
To calculate the solution to the robust optimal control problem, the differential equation (7) is discretised using orthogonal collocation in finite elements, and the bolus injection is implemented as an input to the continuity constraint between sampling times in the prediction. Thus, the resulting optimisation problem does not have integer decisions and is a standard Nonlinear Programming Problem (NLP), which is efficiently solved using IPOPT [Wächter and Biegler, 2006] via CasADi [Andersson et al., 2012] . The constraint on the maximum amount of L is enforced at each collocation point.
Robust nonlinear model predictive control approach
We now apply the multi-stage, scenario-based nonlinear model predictive control [Lucia et al., 2014b [Lucia et al., , 2013 . The monotonicity of the here studied PK/PD model allows for an efficient handling of the uncertainty scenarios as just two uncertainty scenarios are necessary: one for the upper and one for the lower bound.
Model predictive control performs at each measurement point an updated (robust) prediction to obtain the best optimal sequence that robustly satisfies the constraints given the uncertainties in Table 1 . This is done by solving IFAC DYCOPS-CAB, 2016 June 6-8, 2016 . NTNU, Trondheim, Norway Figure 6 shows the same setup, however measurements are taken only every other day.
At first sight, the optimal control of hormone drug dosage seems similar to the intensively studied case of diabetes control. However, measuring the level of EPO in serum takes 2-3 days and in addition to the inconvenience of being a blood test, it cost over US$120.00, see e.g. [WalkIn Lab, 2012] . Thus, reducing the frequency of measuring EPO is advantageous both from a patients' comfort and from a financial point of view. Comparing Figures 5 and 6 shows that a reduced output sampling requires a higher drug dosage, see also Table 2 .
CONCLUSION
This paper first uncovers that the responses of a class of PK/PD models are monotonous in the parameters and in the input. For set-based uncertainties, this monotonicity greatly simplifies the analysis and design of robust optimal controllers. This is illustrated by the example of a PK/PD model of erythropoietin, which also shows that the total amount of drug required for satisfying constraints decreases with more frequent measurements. For each parameter, the monotonicity analysis reveals if increasing it leads to larger of smaller values of each one of the concentrations.
In the case that the underlying model is not monotonic, a robust solution is still possible with similar methods [Lucia et al., 2014a ], but at the cost of much higher IFAC DYCOPS-CAB, 2016 June 6-8, 2016 . NTNU, Trondheim, Norway complexity, due to the necessity of over-approximating reachable sets. Future work will expand the class of models the monotonicity argument can be utilised with.
